

TRACE EYE-D, LLC

SWGDRUG Alignment and Intended-Use Statements

F1 Fentanyl | M-39 Methamphetamine | W-42 Cannabinoid Detection Wipes

Important terminology: These are SWGDRUG alignment and intended-use statements. SWGDRUG does not certify or approve individual commercial presumptive field tests.

These statements are intended for inclusion in agency, laboratory, procurement, or compliance-review packets. They describe how each Trace Eye-D presumptive wipe is positioned relative to the analytical framework in SWGDRUG Recommendations Version 8.2. They do not represent SWGDRUG certification, endorsement, or approval of Trace Eye-D products.

Reference source: Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG), Recommendations Version 8.2, approved June 27, 2024, available from [swgdrug.org](https://www.swgdrug.org).

F1 - Fentanyl Presumptive Detection Wipe

Product	F1 Fentanyl Presumptive Detection Wipe
Manufacturer	Trace Eye-D, LLC
Document Type	SWGDRUG Alignment and Intended-Use Statement
Reference	SWGDRUG Recommendations Version 8.2, Parts III B and IV B

Trace Eye-D F1 is a qualitative colorimetric presumptive screening test intended to provide an observable color response when fentanyl or other substances within the validated response scope of the product are present in a sampled material or residue.

Under SWGDRUG Recommendations Version 8.2, color tests are classified as Category C analytical techniques, which provide general or class-level information rather than structural identification. Accordingly, F1 is intended for use as a presumptive screening component of an analytical scheme and is not represented as a stand-alone confirmatory identification method.

A positive F1 response should therefore be reported or interpreted as a presumptive indication, subject to the user's laboratory or agency procedures. When definitive identification of a controlled substance is required, results should be supported through an appropriate analytical scheme incorporating additional validated techniques in accordance with the applicable jurisdiction and laboratory protocol. SWGDRUG requires laboratories to achieve sufficient overall selectivity for a scientifically supported identification.

The performance characteristics applicable to qualitative testing, including selectivity and interferences, precision, operating range or detection limit, and matrix effects, should be established through appropriate validation or verification for the intended application. SWGDRUG Version 8.2 identifies these characteristics for qualitative methods.

Limitation: F1 is a presumptive field-screening device. A positive color response should not, by itself, be reported as definitive chemical identification of fentanyl.

Common Regulatory and Standards Notice

SWGDRUG does not certify, approve, or endorse individual commercial presumptive test products. This statement describes the intended use and classification of this product relative to the analytical framework contained in SWGDRUG Recommendations Version 8.2. Compliance with SWGDRUG laboratory recommendations ultimately depends upon the analytical scheme, validation or verification, quality system, reporting practices, and jurisdictional requirements of the laboratory or agency using the product.

Reference

Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG). SWGDRUG Recommendations, Version 8.2, approved June 27, 2024. Sections referenced: Part III B, Methods of Analysis and Analytical Scheme for Identification of Drugs or Chemicals; and Part IV B, Validation of Analytical Methods. Source: <https://swgdrug.org/>